Announcements Trials
Browse Landscape

Phase

Phase 3 13Phase 4 4Phase 2 4Phase 1 4Phase 2/3 1Phase 1/2 1

Status

Completed 3Active not recruiting 1

Sponsor Class

OTHER 14INDUSTRY 4NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 2Hirsutism 2Prostate Adenocarcinoma 1Lower Urinary Tract Symptoms 1

Interventions

pembrolizumab 304Paclitaxel 206Carboplatin 200Gemcitabine 173Cisplatin 139Docetaxel 138Cyclophosphamide 136Nivolumab 129Bevacizumab 118Injections 111fludarabine 96atezolizumab 91Pemetrexed 90Dexamethasone 90Cetuximab 90Fluorouracil 84Irinotecan 77Rituximab 72Capecitabine 72venetoclax 71Azacitidine 70130-nm albumin-bound paclitaxel 67Leucovorin 65Fulvestrant 58Oxaliplatin 57durvalumab 56Trastuzumab 56Lenalidomide 55Ipilimumab 55Midazolam 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × bicalutamide × Clear all
NCT04943536 2026-02-27

BiolenRT

Alessa Therapeutics Inc.

Phase 1 Active not recruiting
20 enrolled
Genitourinary

Prostate Adenocarcinoma

NCT04284761 2024-06-24

Biolen-PC

Alessa Therapeutics Inc.

Phase 1 Completed
17 enrolled

Lower Urinary Tract Symptoms

NCT00959335 2017-03-28

Relative Bioavailability Study of Bicalutamide 50 mg Tablet and Casodex Following a 50 mg Dose in Healthy Subjects Under Fasting Conditions

Sandoz

Phase 1 Completed
36 enrolled
Genitourinary

Hirsutism, Prostatic Neoplasms

NCT00960310 2017-03-28

Relative Bioavailability Study of Bicalutamide 50 mg Tablet and Casodex Following a 50 mg Dose in Healthy Subjects Under Fed Conditions

Sandoz

Phase 1 Completed
36 enrolled
Genitourinary

Hirsutism, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡